Equibles does not estimate personal net worth.
Get an email with a short summary when Relay Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get RLAY alertsSanjeev Patel is recorded as CEO at Relay Therapeutics, Inc. (RLAY). Sanjeev Patel has spoken on 7 investor events across 1 company, most recently for Relay Therapeutics, Inc. on September 16, 2026. Relay Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Relay Therapeutics, Inc. includes Thomas Catinazzo (CFO), Brian R. Adams (General Counsel), Claire Mazumdar (Board Member) and 4 others.
“So, yes, as you, first of all, thank you for the invitation, and thank you for all of you attending both online and in person today. 2026 has been a very eventful year for us, exactly as you said.”
“So first of all, thank you for the invitation, and thank you for the grand venue that we're in today. It's been a busy time over the last year for our company. Our mutant-selective PI3K inhibitor, Zovega, has had multiple data that we've disclosed.”
“We've shown three data sets in three large commercial opportunities. The first data set we showed was in second line, hormone receptor positive, HER2 negative breast cancer, or desmotat.”
“Thank you, Pete, for the introduction, and thank you for all of you joining the conference call this morning. Today, we'll share further data on our lead program, Zobagalisib, Zovega for short, our pan-mutant selective PI2K alpha inhibitor, which has the potential to address three very large commercial opportunities.”
“Thank you, Pete, for the introduction, and thank you for all of you joining the conference call this morning. Today, we'll share further data on our lead program, Zobagalisib, Zovega for short, our pan-mutant selective PI2K alpha inhibitor, which has the potential to address three very large commercial opportunities.”
Biotechnology · Healthcare
CEO
